^
Association details:
Biomarker:AR negative
Cancer:HER2 Negative Breast Cancer
Drug Class:Aromatase inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Androgen receptor expression and its prognostic value in T1N0 luminal/HER2- breast cancer

Published date:
03/01/2022
Excerpt:
AR+ tumors were associated with favorable characteristics. AR+ patients had better 5-year recurrence-free survival rates and the risk of recurrence was greater for AR- than for AR+ patients. AR- status predicted the failure of adjuvant endocrine therapy with aromatase inhibitors and of adjuvant chemotherapy with docetaxel plus cyclophosphamide.
DOI:
10.2217/fon-2021-1300